Cattle practitioners pining for Novartis’ antibiotic Framomycin can breath easy now the company has relaunched its 15% injectable solution.
Cattle practitioners pining for Novartis’ antibiotic Framomycin can breath easy now the company has relaunched its 15% injectable solution in the UK and Ireland.
The amino glycoside antimicrobial was originally withdrawn from production two years ago while Novartis reinvested in new manufacturing facilities.
It is licensed to treat bovine mastitis agents including E. coli, Staph. aureus, Klebsiella and A. pyogenes.
Novartis brand manager Eugene Smyth said: “From now on, when a cow is struck with acute bacterial mastitis, Framomycin is again a key tool available to vets to get the cow back on her feet and back to production as quickly as possible.
“Acute bacterial mastitis is devastating and vets are trusted to administer an effective treatment and offer the animal the best chance of recovery – the reintroduction of this well know product gives the practitioner another option to cure these difficult cases.”
Novartis claims the relaunch reaffirms its focus on cattle health.